Benzinga - by Benzinga Insights, Benzinga Staff Writer.
Jeffrey Del Carmen, Chief Commercial Officer at Catalyst Pharmaceuticals (NASDAQ:CPRX), executed a substantial insider sell on June 11, according to an SEC filing.
What Happened: Carmen opted to sell 7,541 shares of Catalyst Pharmaceuticals, according to a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The transaction's total worth stands at $121,183.
In the Wednesday's morning session, Catalyst Pharmaceuticals's shares are currently trading at $15.76, experiencing a up of 1.29%.
Get to Know Catalyst Pharmaceuticals Better Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Understanding the Numbers: Catalyst Pharmaceuticals's Finances Revenue Growth: Catalyst Pharmaceuticals displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 15.4%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Interpreting Earnings Metrics:
- Gross Margin: Achieving a high gross margin of 87.29%, the company performs well in terms of cost management and profitability within its sector.
- Earnings per Share (EPS): Catalyst Pharmaceuticals's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.2.
Valuation Metrics: A Closer Look
- Price to Earnings (P/E) Ratio: The P/E ratio of 27.79 is lower than the industry average, implying a discounted valuation for Catalyst Pharmaceuticals's stock.
- Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 4.39, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): The company's EV/EBITDA ratio 13.42 is below the industry average, indicating that it may be relatively undervalued compared to peers.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Key in Investment Decisions Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
Transaction Codes Worth Your Attention When analyzing transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.